BioGeneration Ventures secures €66m for European biotech fund
BioGeneration Ventures (BGV) announces an investment by the European Investment Fund (EIF) and other new investors in BGV III...
List view / Grid view
BioGeneration Ventures (BGV) announces an investment by the European Investment Fund (EIF) and other new investors in BGV III...
Numab Therapeutics announced a collaboration and option agreement with Kaken Pharmaceutical for the identification of a multispecific antibody candidate for development in inflammatory disease.
Kymab Group Limited, a leading human monoclonal antibody biopharmaceutical group, announces the appointment of Dr Sonia Quaratino as its first Chief Medical Officer. Dr Quaratino will manage the clinical development of the Group's expanding therapeutic antibody portfolio.
The successful combination of two therapies results in the growth of specialised vessels that deliver cancer-fighting immune cells to a tumour, potentially leading to more effective treatments and longer survival periods.
Enables real-time measurements of cell health, proliferation, movement and function while cells remain unperturbed in a physiologically relevant environment...
The IntelliCyt Cy-Clone™ PLUS Assay System will accelerate and improve the quality of clone ranking and selection for developing cell lines which can reduce production costs of biopharmaceuticals...
Plasticell, a developer of stem cell technologies and cell-based therapies, has signed agreements with the Agency for Science, Technology and Research (A*STAR) and the Nanyang Technological University (NTU) to progress its therapeutic stem cell pipeline.
Lone Friis and David Matthews discuss developability assessment of therapeutic antibodies, and Negin Mokhtari and colleagues explain nanoparticle-mediated enzyme delivery for application in cancer therapy...
Cancer Research UK announced that four international teams are the first recipients of its global £100m Grand Challenge competition, which aims to overcome the biggest challenges facing cancer researchers in a global effort to beat cancer sooner.
Charles River Laboratories has provided a progress update related to its support of Moderna Therapeutics’ nonclinical discovery and development efforts...
Macrophage Pharma, a newly formed immune-oncology company, has successfully raised £9 million in a Series A equity financing round.
4 November 2016 | By Niamh Louise Marriott, Digital Content Producer
Øystein Soug is the former CFO of Algeta, a Norwegian oncology biotech company which was sold to Bayer for USD 2.9 billion in 2014...
14 July 2016 | By Victoria White, Digital Content Producer
F-star and the CD Laboratory seek to progress the understanding of the design, development and unique biology of antibody and antibody-based therapeutics...
2 June 2016 | By Victoria White, Digital Content Producer
The 'Toulouse Cancer Santé' Foundation and the Pierre Fabre have launched a new research team within the Cancer Research Centre of Toulouse...
18 April 2016 | By Victoria White, Digital Content Producer
IPI-549 is an orally administered immuno-oncology development candidate that selectively inhibits phosphoinositide-3-kinase gamma (PI3K-gamma)...